Microwave Breast Imaging Using Rotational Bistatic Impulse Radar for the Detection of Breast Cancer: Protocol for a Prospective Diagnostic Study

Shinsuke Sasada¹, MD, PhD; Norio Masumoto¹, MD, PhD; Hang Song², PhD; Akiko Emi¹, MD, PhD; Takayuki Kadoya¹, MD, PhD; Koji Arihiro³, MD, PhD; Takamaro Kikkawa², PhD; Morihito Okada¹, MD, PhD

¹Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
²Research Institute for Nanodevice and Bio Systems, Hiroshima University, Higashi-hiroshima, Japan
³Department of Anatomical Pathology, Hiroshima University Hospital, Hiroshima, Japan

Corresponding Author:
Shinsuke Sasada, MD, PhD
Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine
Hiroshima University
1-2-3 Kasumi, Minami-Ku
Hiroshima, 734-8551
Japan
Phone: 81 82 257 5869
Fax: 81 82 256 7109
Email: shsasada@hiroshima-u.ac.jp

Abstract

Background: Mammography is the standard examination for breast cancer screening; however, it is associated with pain and exposure to ionizing radiation. Microwave breast imaging is a less invasive method for breast cancer surveillance. A bistatic impulse radar–based breast cancer detector has recently been developed.

Objective: This study aims to present a protocol for evaluating the diagnostic accuracy of the novel microwave breast imaging device.

Methods: This is a prospective diagnostic study. A total of 120 participants were recruited before treatment administration and divided into 2 cohorts: 100 patients diagnosed with breast cancer and 20 participants with benign breast tumors. The detector will be directly placed on each breast, while the participant is in supine position, without a coupling medium. Confocal images will be created based on the analyzed data, and the presence of breast tumors will be assessed. The primary endpoint will be the diagnostic accuracy, sensitivity, and specificity of the detector for breast cancer and benign tumors. The secondary endpoint will be the safety and detectability of each molecular subtype of breast cancer. For an exploratory endpoint, the influence of breast density and tumor size on tumor detection will be investigated.

Results: Recruitment began in November 2018 and was completed by March 2020. We anticipate the preliminary results to be available by summer 2021.

Conclusions: This study will provide insights on the diagnostic accuracy of microwave breast imaging using a rotational bistatic impulse radar. The collected data will improve the diagnostic algorithm of microwave imaging and lead to enhanced device performance.

Trial Registration: Japan Registry of Clinical Trials jRCTs062180005; https://jrcr.nih.go.jp/en-latest-detail/jRCTs062180005

International Registered Report Identifier (IRRID): DERR1-10.2196/17524

(JMIR Res Protoc 2020;9(10):e17524) doi: 10.2196/17524

KEYWORDS

breast cancer; microwave imaging; diagnostic accuracy; screening; ultra-wideband radar
Introduction

Background
The incidence of breast cancer is increasing, and the breast is the leading cancer location for women both worldwide and in Japan [1,2]. Mammography has been demonstrated to be effective in reducing breast cancer mortality and has become a standard screening method [3]. However, the screening rate of breast cancer varies greatly across countries; in Japan, it was 42.3% in 2016, which is lower than that in other developed countries [4,5]. The reasons for this lower rate of breast cancer screening could be the experience of pain by compression and exposure to ionizing radiation in mammography [6,7]. Therefore, painless and radiation exposure–free methodologies are required for the screening of breast cancer. In addition, mammography relies on the contrast in the X-ray attenuation coefficient between a normal mammary gland and malignant tissue, which can be as small as 1:1.1 [8]. This low contrast leads to lower sensitivity of mammography screening, particularly in dense breast tissue [6,7,9,10].

Microwave Breast Imaging
Microwave breast imaging has developed significantly in the recent years [10,11]. The physical basis for microwave breast imaging consists of the difference in dielectric properties between the normal breast and cancerous tissues. The normal breast primarily consists of adipose tissue (low dielectric properties) with dispersed distributions of mammary glands (higher dielectric properties). Cancer tissue has greater dielectric properties at a frequency of 0.5GHz-50 GHz. A high contrast between healthy and cancerous tissues has been previously reported [12-17]. Among microwave breast imaging systems, the radar-based technology that uses time of flight of the impulse radio ultra-wideband (IR-UWB) signal is widely applied due to the simplicity and robustness of calculation [18-23]. This approach can calculate the amount of scattered electromagnetic energy at any spatial position to reconstruct an energy map of the object. The radar-based imaging method was developed in 1998, and it is referred to as confocal microwave imaging [18,19]. Synthetic focusing was performed under the assumption that the dielectric constant of breast was homogeneous. The electromagnetic signals scattered from the target location were calculated based on the signal path between the transmitter and receiver antennas and the average propagation speed of microwave radiation. This method reconstructs an energy map, which shows the qualitative position of the highest intensity of the confocal image of the scattered signals. In addition, the bistatic radar system, which allows different aspects of a target to be visualized, can deliver more information than the monostatic systems [24-29].

Some microwave breast imaging systems have already been evaluated in clinical settings. The largest cohort studies have been conducted with 86 and 223 patients using the Multistatic Array Processing for Radiowave Image Acquisition (MARIA) system [26,30]. Results indicated that the sensitivity of breast cancer detection was 74%-75%. Studies using other systems have also been conducted, and the results from 150 females with abnormal mammograms indicated a mean increase in the image contrast of 150%-200% between abnormal and normal breast tissues [31-33]. However, these conventional prototypes use vector network analyzers, resulting in heavy instrumentation and high cost. Although some groups have developed compact microwave imaging systems [27-29,34,35], these systems are yet to be applied in clinical settings.

Preliminary Work
We developed a prototype handheld bistatic radar–based system using complementary metal–oxide–semiconductor (CMOS)-integrated circuits [36-41]. In a clinical pilot study, this system showed a 100% sensitivity in 5 patients with breast cancer [42]. Information on specificity and causes of false positives using this microwave imaging technology has not yet been clarified. Therefore, we aim to determine the diagnostic performance of our in-house bistatic radar–based detector with patients with breast cancer or those with benign breast tumors.

Purpose
This study has 3 major goals. It aims to assess the sensitivity and specificity of the system in screening for breast cancer, assess the sensitivity and specificity of the system screening for benign tumors, and investigate the impact of tumor biology based on the measured results.

Methods

Study Design
This study is a single-center, single-arm, prospective diagnostic study on women with breast tumors and will be performed as a specified clinical trial under the Japanese law on clinical research (the Clinical Trials Act). Women with breast cancer or benign breast tumors as diagnosed by conventional examinations were recruited for this purpose. An examination using the handheld bistatic radar–based breast imaging system will be performed before any treatment. The flowchart and time schedule for this study are shown in Figure 1 and Table 1, respectively.
Figure 1. Study flowchart.

Table 1. Time schedule of the study.

| Procedure                              | Baseline | Enrollment (week 0) | Intervention and assessment (week 0 to week 8) |
|----------------------------------------|----------|---------------------|-----------------------------------------------|
| Clinical breast imaginga                | ✓        |                     |                                               |
| Pathological examination               | ✓        |                     |                                               |
| Informed consent                       | ✓        |                     |                                               |
| Confirmation of eligibility criteria   | ✓        |                     |                                               |
| Study examination                      | ✓        |                     |                                               |
| Safety                                 | ✓        |                     |                                               |

aConducted by mammography, breast ultrasonography, contrast-enhanced breast magnetic resonance imaging, or fluorodeoxyglucose positron emission tomography.

The Certified Review Board of the Hiroshima University Hospital approved this study (CRB6180006) on October 3, 2018 (version 1). All procedures will be in accordance with the Japanese law (the Clinical Trials Act), the Declaration of Helsinki, and comparable ethical standards. This study is covered by clinical research insurance, and compensation is provided. Written informed consents will be obtained from all study participants.

Study Population

Participants were recruited from the Hiroshima University Hospital and were classified into 2 groups: cohort 1, comprising 100 women with histologically diagnosed breast cancer; and cohort 2, comprising 20 women with histologically or radiologically diagnosed benign breast tumors.

The inclusion criteria included (1) female patients older than 20 years; (2) those with histologically confirmed breast cancer (only for cohort 1); (3) those with confirmed breast tumor by 1 or more arbitrary imaging examinations, such as mammography, breast ultrasonography, contrast-enhanced breast magnetic resonance imaging, or fluorodeoxyglucose positron emission tomography; and (4) those who provide a written informed consent. The exclusion criteria included (1) history of chemotherapy or radiotherapy within 6 months prior to registration; (2) hypersensitivity to the acrylonitrile butadiene styrene (ABS) plastic resin; (3) presence of a pacemaker; or (4) a physician's decision. Participant examination will be discontinued and their data will be removed in case of withdrawal of consent, eligibility, inability to participate in the study due to disease progression or complications, death, induction of treatment before the study, or any other exclusion criterion deemed necessary by the investigators. Benign breast tumors will be diagnosed by the Breast Imaging Reporting and Data System (BI-RADS) (ultrasound category 2 or less), fine-needle aspiration, or core needle biopsy. The radiological images will be read by 2 experienced radiologists.

Study Examination

Measurements and weight of the handheld detector are 19.1 × 17.7 × 18.8 cm and 2 kg, respectively. It consists of a handle,
step motor, control module, radio frequency module, and dome
antenna array. The structure of the detector is depicted in Figure
2A. The system is composed of CMOS-integrated circuits that
enable the generation and transmission of Gaussian monocycle
pulse (GMP) trains and the control of the combination of a 4 ×
4 cross-shaped dome antenna array, using a single-pole 8-throw
switching matrix (SP8T-SW). The dome antenna array consists
of 16 elements, and each antenna element is composed of a
square slot set in a ground plane on 1 side of a Duroid RT 6010
substrate. The center frequency and the bandwidth of the
ultra-wideband antenna are 6 GHz and 6.7 GHz, respectively.
The dome shell is composed of ABS to hold the antennae in
place. The dome antenna will be placed on each breast without
any coupling liquid with the participant in a supine position and
held by hand or supported by a stand to keep the device
stationary. A transmitter antenna array emits GMP signals with
the pulse duration of 160 picoseconds at a repetition frequency
of 100 MHz to illuminate the breast tumor, and a receiver
antenna receives the reflected signal. The antenna array rotates
in 9 steps from 0° to 360° using a step motor. A single inspection
can yield 40 sets of data with 2048 measurement points acquired
within 5 minutes for each breast. The received signals are
converted from analog to digital via a 12-bit analog-to-digital
converter, and a confocal image is constructed (Figure 2B).

Study Endpoints
The primary endpoint is the detection sensitivity and specificity
for breast cancer or benign breast tumors by the screening
system. Contralateral healthy breasts will also be measured in
this study, and the diagnostic accuracy will be calculated on a
per-breast basis. The secondary endpoints are sensitivity for
breast cancer detection according to the different molecular
subtypes, sensitivity for benign breast tumors according to
histology, and feasibility of the examination. The biology of
breast cancer will be pathologically evaluated by surgery or
using collected biopsy specimens. For exploratory purposes,
the influence of tumor size and breast density on the detectability
of breast tumor will also be investigated.

Sample Size Calculation
Sample size calculations were based on the sensitivity of breast
cancer detection and the significance of breast cancer screening.
The expected sensitivity was set at 80% with reference to the
sensitivity of the Japanese mammography screening [43]. The
required sample size was 171 breasts according to a width of
the 95% CI being set to 0.12 at one-sided α=.05. Therefore, a
sample size of 100 women (200 breasts) in cohort 1 was
proposed.

Data Security and Analysis
Data will be entered directly in a database and kept in a secure
network computer in a locked office at the Hiroshima
University. All information will be uniquely anonymized. The
operational process of this study will be subject to annual
monitoring, and no audit is required. The occurrence of serious
adverse events will be reported to the Certified Review Board
of the Hiroshima University Hospital or the Ministry of Health,
Labor and Welfare of Japan. Raw data from measurements will
be analyzed using customized software that was independently
developed to control the operation of the detector. Statistical
analysis will be performed using the R statistical software (R
Foundation for Statistical Computing) environment.
Results

Recruitment began in November 2018 and was completed by March 2020. We expect to submit the results for publication by summer 2021.

Discussion

Overview

Some microwave breast imaging systems have been previously developed and clinically investigated [11]. Of these, 2 systems were considered in clinical studies with large cohorts and suggested their potential utility in the clinical settings [30,32]. These studies focused solely on sensitivity, but the diagnostic accuracy (including specificity) of these systems has not been reported. To the best of our knowledge, this study is the first of its kind that focuses on both sensitivity and specificity of a microwave breast imaging system on a per-breast basis.

Our imaging system has several advantages in addition to the general features of microwave imaging. First, it is an easy-to-operate system, where an operator simply places the device in close contact with a breast and presses a start switch. No special training is required for the examinations, and the system is not affected by differences of technical skills of its operators. Second, this system places compact integrating antennae, excitation and acquisition hardware, and signal routing in a single unit. The high portability will provide a significant benefit for remote inspection [44]. Additionally, this compact system can be used repeatedly at low cost and is useful for monitoring applications. The advantages of this system make it suitable for breast cancer screening, although concerns regarding the production of mechanical heat and influence on pacemakers need to be assessed. In the prestage experiment, the temperature of the device after 30 minutes of operation was 30 degrees, and thus the burn risk was minimal. In addition, this study will exclude individuals with a pacemaker. Therefore, the risk associated with this study is low. Data obtained in this study will be helpful for future system improvements. This study will also provide important information on factors that lead to the false positives in breast lesions and differentiation between benign and malignant lesions.

Limitations

This study targets breast tumor cases. The diagnostic accuracy of this screening system cannot be evaluated on a per-person basis in clinical settings. In addition, the data analysts will be blind to whether breast tumors are on the left or right because of the influence of the interpretation of the test data.

Conclusions

We expect that this study will demonstrate the clinically meaningful diagnostic accuracy of the bistatic IR-UWB radar–based breast imaging system. We also hope that this study will propose a novel methodology for breast cancer screening and contribute to improvements in the current technical equipment.

Acknowledgments

This study is only possible due to the participating patients. We would like to thank Kayo Fukui, Akiko Kanou, and Erika Yokoyama for the assistance with examination. This work is supported by JSPS KAKENHI Grant Number JP18K15321/20K16444. This work is also supported partly by the Cooperative Research Project of Research Center for Biomedical Engineering and the MIC/SCOPE # 185008001. The funding bodies are not involved in the design of the study; collection, analysis, and interpretation of data; and writing and reviewing of the manuscript.

Conflicts of Interest

None declared.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin 2019 Jan 08;69(1):7-34 [FREE Full text] [doi: 10.3322/caac.21551] [Medline: 30620402].
2. Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, Japan Cancer Surveillance Research Group. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2015 Sep;45(9):884-891. [doi: 10.1093/jjco/hyv088] [Medline: 26142437].
3. Nelson H, Cantor A, Humphrey L, Fu R, Pappas M, Daeges M, et al. Screening for Breast Cancer: A Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation. Rockville (MD): Agency for Healthcare Research and Quality (US); Jan 2016.
4. OECD Health Statistics 2018. URL: https://stats.oecd.org/index.aspx?DataSetCode=HEAL_STAT [accessed 2019-08-21].
5. Foundation for Promotion of Cancer Research. Cancer statistics in Japan 2018. URL: https://g얀jo.jo/data/reg_stat/statistics/brochure/2018/cancer_statistics_2018.pdf [accessed 2019-08-21].
6. Nelson HD, Pappas M, Cantor A, Griffin I, Daeges M, Humphrey L. Harms of Breast Cancer Screening: Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med 2016 Feb 16;164(4):256-267 [FREE Full text] [doi: 10.7326/M15-0970] [Medline: 26756737].
7. Hamashima C, Japanese Research Group for the Development of Breast Cancer Screening Guidelines, Hamashima C, Hattori M, Honjo S, Kasahara Y, Japanese Research Group for the Development of Breast Cancer Screening Guidelines.
8. Johns PC, Yaffe MJ. X-ray characterisation of normal and neoplastic breast tissues. Phys Med Biol 1987 Jun;32(6):675-695. [doi: 10.1088/0031-9155/32/6/002] [Medline: 3039542]

9. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007 Jan 18;356(3):227-236. [doi: 10.1056/NEJMoa062790] [Medline: 17229950]

12. Sugitani T, Kubota S, Kuroki S, Sogo K, Arihiro K, Okada M, et al. Complex permittivities of breast tumor tissues obtained from cancer surgeries. Appl. Phys. Lett. 2014 Jun 27;104(25):253702. [doi: 10.1063/1.4885087]

17. Surowiec AJ, Stuchly SS, Barr JB, Swarup A. Dielectric properties of breast carcinoma and the surrounding tissues. IEEE Trans Microwave Theory Tech 2015 Nov;64(11):2986-2994. [doi: 10.1109/TMI.2016.2518489] [Medline: 29993488]

20. Xu Li, Bond E, Van Veen B, Hagness S. An overview of ultra-wideband microwave imaging via space-time beamforming for early-stage breast-cancer detection. IEEE Antennas Propag. Mag 2005 Feb;47(1):19-34. [doi: 10.1109/map.2005.1436217]

23. Byrne D, Sarafianou M, Craddock IJ. Compound Radar Approach for Breast Cancer Detection. IEEE Trans Biomed Eng 2016 Mar;63(3):530-539. [doi: 10.1109/TBME.2015.2465867] [Medline: 26259214]

27. Porter E, Moeller M, Boyce J, Popovic M. An Early Clinical Study of Time-Domain Microwave Radar for Breast Health Monitoring. IEEE Trans Biomed Eng 2016 Mar;63(3):530-539. [doi: 10.1109/TBME.2015.2465867] [Medline: 26259214]

28. Porter E, Bahrami H, Santorelli A, Popovic M. A Wearable Microwave Antenna Array for Time-Domain Breast Tumor Screening. IEEE Trans Med Imaging 2016 Jun;35(6):1501-1509. [doi: 10.1109/TMI.2016.2518489] [Medline: 26780788]

29. Santorelli A, Porter E, Kang E, Piske T, Popovic M, Schwartz JD. A Time-Domain Microwave System for Breast Cancer Detection Using a Flexible Circuit Board. IEEE Trans. Instrum. Meas 2015 Nov;64(11):2986-2994. [doi: 10.1109/TIM.2015.2440565]
30. Massey H, Ridley N, Lyburn I, Jones L, Taylor S, Schoenleber-Lewis M, et al. Radio-wave detection of breast cancer in the symptomatic clinic: a multi-centre study. 2017 Jul Presented at: International Cambridge Conference on Breast Cancer Imaging; Jul 2017; Cambridge, UK.

31. Poplack SP, Paulsen KD, Hartov A, Meaney PM, Pogue BW, Tosteson TD, et al. Electromagnetic breast imaging: average tissue property values in women with negative clinical findings. Radiology 2004 May;231(2):571-580. [doi: 10.1148/radiol.2312030606] [Medline: 15128998]

32. Poplack SP, Tosteson TD, Wells WA, Pogue BW, Meaney PM, Hartov A, et al. Electromagnetic breast imaging: results of a pilot study in women with abnormal mammograms. Radiology 2007 May;243(2):350-359. [doi: 10.1148/radiol.2432062836] [Medline: 17400760]

33. Meaney PM, Fanning MW, Raynolds T, Fox CJ, Fang Q, Kogel CA, et al. Initial clinical experience with microwave breast imaging in women with normal mammography. Acad Radiol 2007 Feb;14(2):207-218 [FREE Full text] [doi: 10.1016/j.acra.2006.10.016] [Medline: 17236994]

34. Mobashsher AT, Mahmoud A, Abbosh AM. Portable Wideband Microwave Imaging System for Intracranial Hemorrhage Detection Using Improved Back-projection Algorithm with Model of Effective Head Permittivity. Sci Rep 2016 Feb 04;6:20459 [FREE Full text] [doi: 10.1038/srep20459] [Medline: 26842761]

35. Bassi M, Caruso M, Khan MS, Bevilacqua A, Capobianco A, Neviani A. An Integrated Microwave Imaging Radar With Planar Antennas for Breast Cancer Detection. IEEE Trans Micro Theory Tech 2013 May;61(5):2108-2118. [doi: 10.1109/tmtt.2013.2247052]

36. Sugitani T, Kubota S, Toya A, Xiao X, Kikkawa T. A Compact 4 × 4 Planar UWB Antenna Array for 3-D Breast Cancer Detection. Antennas Wireless Propag Lett 2013 Dec;12:733-736. [doi: 10.1109/lawp.2013.2270933]

37. Sugitani T, Kubota S, Hafiz M, Xiao X, Kikkawa T. Three-dimensional confocal imaging for breast cancer detection using CMOS Gaussian monocycle pulse transmitter and 4 × 4 ultra wideband antenna array with impedance matching layer. Jpn J Appl Phys 2014 Mar 05;53(4S):04EL03. [doi: 10.7567/jjap.53.04el03]

38. Kubota S, Toya A, Sugitani T, Kikkawa T. 5-Gb/s and 10-GHz Center-Frequency Gaussian Monocycle Pulse Transmission Using 65-nm Logic CMOS With On-Chip Dipole Antenna and High-κ Interposer. IEEE Trans Compon Packag Manufact Technol 2014 Jul;4(7):1193-1200. [doi: 10.1109/tcmt.2014.2320497]

39. Song H, Kono H, Seo Y, Azhari A, Somei J, Suematsu E, et al. A radar-based breast cancer detection system using CMOS integrated circuits. IEEE Access 2015;3:2111-2121. [doi: 10.1109/access.2015.2496101]

40. Azhari A, Sugitani T, Xiao X, Kikkawa T. DC–17-GHz CMOS single-pole-eight-throw switching matrix for radar-based image detection. Jpn J Appl Phys 2016 Nov 17;55(12):127301. [doi: 10.7567/jjap.55.127301]

41. Song H, Azhari A, Xiao X, Suematsu E, Watanabe H, Kikkawa T. Microwave Imaging Using CMOS Integrated Circuits with Rotating 4 × 4 Antenna Array on a Breast Phantom. Int J Antennas Propag 2017;2017:1-13. [doi: 10.1155/2017/6757048]

42. Sasada S, Masamoto N, Song H, Kajitani K, Eni A, Kadoya T, et al. Portable impulse-radar detector for breast cancer: a pilot study. J Med Imaging (Bellingham) 2018 Apr;5(2):025502 [FREE Full text] [doi: 10.1117/1.JMI.5.2.025502] [Medline: 29900185]

43. Ohuchi N, Suzuki A, Sobue T, Kawai M, Yamamoto S, Zheng Y, et al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial. Lancet 2016 Jan 23;387(10016):341-348. [doi: 10.1016/S0140-6736(15)00774-6] [Medline: 26547101]

44. Leung J, McKenzie S, Martin J, McLaughlin D. Effect of rurality on screening for breast cancer: a systematic review and meta-analysis comparing mammography. Rural Remote Health 2014;14(2):2730 [FREE Full text] [Medline: 24953122]

Abbreviations

ABS: acrylonitrile butadiene styrene
BI-RADS: Breast Imaging Reporting and Data System
CMOS: complementary metal–oxide–semiconductor
GMP: Gaussian monocycle pulse
IR-UWB: impulse radio ultra-wideband
MARIA: Multistatic Array Processing for Radiowave Image Acquisition
SP8T-SW: single-pole 8-throw switching matrix
